Background: Health related quality of life (HRQOL) is a pivotal concern for early stage prostate cancer survivors and their spouses. Recent developments, including the emergence of brachytherapy (BT), the development of 3-D conformal radiotherapy (3D-ERT), the increased use of adjuvant hormonal therapy, and the observation that radical prostatectomy (RP) outcomes may differ between practitioners, fuel a need to re-evaluate HRQOL outcomes in this context. HRQOL following BT, 3D-ERT, and RP have not been characterized with an instrument validated to detect effects of each of these interventions. Moreover, patient or provider determinants of patient HRQOL, patient satisfaction, and spouse satisfaction remain uncharacterized. Because prostate cancer survivors and experts determined that existing HRQOL instruments lacked key items for concurrently evaluating HRQOL effects of BT, ERT, and RP, we developed and validated the Expanded Prostate Cancer Index Composite (EPIC) instrument using a cohort that equally represented each of these 3 interventions. Factor analysis revealed 2 new HRQOL domains (urinary-irritative and hormonal) complementing the 3 function domains of UCLA-PCI (urinary-incontinence, bowel, sexual). The 5 HRQOL domains measured by EPIC showed satisfactory internal consistency, reliability, and external validity. Cross-sectional HRQOL comparison among 1014 BT, 3D-ERT, or RP survivors and controls showed that each EPIC HRQOL domain was adversely affected by at least one of the therapies. EPIC HRQOL domain scores associated significantly with patient satisfaction and were sensitive to baseline factors such as age, cancer severity, and prostate size. We hypothesize that patient and provider characteristics affect HRQOL changes after brachytherapy, external radiation, or prostatectomy, and that these interventions have different HRQOL effects, which impact long-term patient and spouse satisfaction. The proposed observational study has the following Specific Aims: 1) To assess baseline determinants, including provider characteristics, of long-term HRQOL after BT, 3D-ERT, or RP; 2) To characterize baseline determinants of patient and spouse satisfaction with intervention process and outcome; and 3) To evaluate effects of therapy choice on HRQOL outcome and satisfaction. Experimental Design: A prospective, observational, multi-institutional study will be performed at 5 institutions with pre-existing, multi-disciplinary expertise in BT, 3D-ERT, and RP. Patients with early stage prostate cancer electing to undergo BT, 3D-ERT, or RP as primary therapy will be eligible. Baseline demographics, cancer severity measures, and provider characteristics will be recorded, while HRQOL will be measured using the EPIC survey instrument administered at baseline (pre-therapy); then at 2 months, 6 months, and yearly after therapy for 3 years. The multidimensional SSS-10 instrument, administered to survivors and their spouses or life partners, will measure satisfaction with process and outcome. The principal endpoints will be changes in EPIC domain summary scores from baseline to two years after therapy, and survivor satisfaction as well as spouse satisfaction. For each procedure, HRQOL changes over time and yearly satisfaction scores will be modeled by a mixed effects model; baseline risk factors that affect change will be identified. The effects of each therapy on change in HRQOL will be compared after controlling for risk factors identified in the previous step. The findings from this prospective, observational study will provide benchmarks to guide outcomes expectations and to facilitate evidence-based decisions regarding therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA095662-03
Application #
6900059
Study Section
Special Emphasis Panel (ZRG1-SNEM-4 (01))
Program Officer
Jeffery, Diana D
Project Start
2002-07-01
Project End
2007-06-30
Budget Start
2004-09-24
Budget End
2005-06-30
Support Year
3
Fiscal Year
2004
Total Cost
$612,250
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Chang, Peter; Regan, Meredith M; Ferrer, Montserrat et al. (2017) Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. J Urol 197:376-384
Gay, Hiram A; Sanda, Martin G; Liu, Jingxia et al. (2017) External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. Int J Radiat Oncol Biol Phys 98:304-317
Skolarus, Ted A; Dunn, Rodney L; Sanda, Martin G et al. (2015) Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology 85:101-5
Evans, Joseph R; Zhao, Shuang; Daignault, Stephanie et al. (2015) Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 116:179-84
Gilbert, Scott M; Sanda, Martin G; Dunn, Rodney L et al. (2014) Satisfaction with information used to choose prostate cancer treatment. J Urol 191:1265-71
Hoppe, Bradford S; Michalski, Jeff M; Mendenhall, Nancy P et al. (2014) Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer 120:1076-82
Chipman, Jonathan J; Sanda, Martin G; Dunn, Rodney L et al. (2014) Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol 191:638-45
StorĂ¥s, Anne Holck; Sanda, Martin G; Ferrer, Montse et al. (2014) Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment. Clin Genitourin Cancer 12:e117-25
Gray, Phillip J; Paly, Jonathan J; Yeap, Beow Y et al. (2013) Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 119:1729-35
Harden, Janet; Sanda, Martin G; Wei, John Thomas et al. (2013) Survivorship after prostate cancer treatment: spouses' quality of life at 36 months. Oncol Nurs Forum 40:567-73

Showing the most recent 10 out of 34 publications